

Referenties bij Bioboel, Psychosociale Oncologie 2024 (4)

Abbasi AB, Curtis LH, Califf RM. Why should the FDA focus on pragmatic clinical research? JAMA 2024; published online June 3.

Angus DC, Huang AJ, Lewis RJ, Abernethy AP, Califf RM, Landray M, ..., for the JAMA summit on clinical trials participation. The integration of clinical trials with the practice of medicine – repairing a house divided. JAMA 2024; published June 3.

Booth CM, Eisenhauer EA, Gyawali B, Tannock IF. Progression-free survival should not be used as a primary end point for registration of anticancer drugs. J Clin Oncol 2023;41:4968-4972.

Booth CM, Eisenhauer EA, Gyawali B, Tannock IF. Reply to D.J. Stewart et al. J Clin Oncol 2024;42:974.

Bretthauer M, Wieszczy P, Løberg M, Kaminski MF, Werner TJ, Helsing LM, ..., Kalager M. Estimated lifetime gained with cancer screening tests. A meta-analysis of randomized clinical trials. JAMA Intern Med 2023;183:1196-1203.

Buck E, Haslam A, Tuia J, Prasad V. Frequency and characteristics of trials using medical writer support in high-impact oncology journals. JAMA Network Open 2023;6:e2254405.

Buiting HM, Sonke GS. Gray oncologic areas. J Surg Oncol 2024;129:1013-1014.

Buiting HM, van der Linden Y, Steenbruggen TG, Bolt EE, van Houdt W, Sonke GS. Oligometastases: incorporate the patient perspective to ensure optimal treatment and care. J Surg Oncol 2024;129:679-680.

Cella D, Nolla K, Peipert JD. The challenge of using patient reported outcome measures in clinical practice: how do we get there? J Pat Rep Outcom 2024, in druk.

Chalabi M, Verschoor YL, Tan PB, Balduzzi S, van Lent AU, Grootcholten C, ..., Haanen JB. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. New Engl J Med 2024;390:1949-1958.

Chen EY, Haslam A, Prasad V. FDA acceptance of surrogate end points for cancer drug approval: 1992-2019. JAMA Intern Med 2020;180:912-914.

Conforti F, Pala L, Bagnardi V, de Pas T, Colleoni M, Buyse M,, Gelber RD. Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer. Critical analysis of strengths, weaknesses, and misinterpretations. JAMA Oncol 2022;8:1668-1675.

Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, ..., Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014;32:1277-1280.

Feeney T, Villanueva T, Price A. Communicating the benefits and harms of anticancer drugs. BMJ 2023;380:623.

Gyawali B, Eisenhauer E, Tregear M, Booth CM. Progression-free survival: it is time for a new name. Lancet Oncol 2022;23:328-330.

Iskander R, Moyer H, Vigneault K, Mahmud SM, Kimmelman J. Survival benefit associated with participation in clinical trials of anticancer drug: A systematic review and meta-analysis. JAMA 2024;publ May 20.

Ito C, Hashimoto A, Uemura K, Oba K. Misleading reporting (Spin) in noninferiority randomized clinical trials in oncology with statistically not significant results: a systematic review. JAMA Netw Open 2021;4:e2135765.

Keizer, B. Het refrein is Hein. Nijmegen, SUN, 1994.

Leary A, Besse B, André F. The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology. Lancet 2024;403:406-408.

Liu ITT, Kesselheim AS, Scheffer Cliff ER. Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval. JAMA 2024;331:1471-1479.

Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D, ..., on behalf of the ESMO Guidelines Committee. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline. *Ann Oncol* 2022;33:878-892.

Millar N, Batalo B, Budgell B. Promotional language (Hype) in abstracts of publications of National Institutes of Health-funded research, 1985-2020. *JAMA Network Open* 2023;6:e2348706.

Porzsolt F, Matosevic R, Kaplan RM. Recommendations for cancer screening would be different if we measured endpoints that are valid, reliable, specific, and important to patients. *Cancer Causes Contr* 2020;31:705-711.

Shahzad M, Naci H, Wagner AK. Estimated Medicare spending on cancer drug indications with a confirmed lack of clinical benefit after US Food and Drug Administration accelerated approval. *JAMA Intern Med* 2021;181:1673-1675.

Sobrero AF, Pastorino A, Zalcberg JR. You're cured till you're not: Should disease-free survival be used as a regulatory or clinical end point for adjuvant therapy of cancer? *J Clin Oncol* 2022;40:4044-4047.

Sonke GK. Duur: ja, effectief: niet per se. *NRC Handelsblad* 2023 17 juni, katern Wetenschap.

Tannock IF, Pond GR, Booth CM. Biased evaluation in cancer drug trials – how use of progression-free survival as the primary end point can mislead. *JAMA Oncol* 2022;8:679-680.

Wong BO, Clapp JT, Morris AM. Misinterpretation of surgeons' statements on cancer removal – The adverse effects of “We got it all”. *JAMA Oncol* 2022;8:1563-1564.

Wright K, Mittal A, Gyawali B. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls. *Curr Opin Oncol* 2023;35:513-521.